Dmk Pharmaceuticals CORP

Market Movers (8-K)

DMKPQ
Dmk Pharmaceuticals CORP
8-K: DMK Pharmaceuticals Completes Asset Sale and Announces Board and Executive Resignations Following Bankruptcy
DMK Pharmaceuticals has sold its ZIMHI assets for $3.17 million and announced the resignation of its board and CEO, effective June 27, 2024, following its Chapter 11 bankruptcy filing.
Worse than expected
DMKPQ
Dmk Pharmaceuticals CORP
8-K: DMK Pharmaceuticals Faces Nasdaq Delisting After Trading Suspension
DMK Pharmaceuticals Corporation received notice of its impending delisting from the Nasdaq Capital Market following a trading suspension.
Worse than expected
DMKPQ
Dmk Pharmaceuticals CORP
8-K: DMK Pharmaceuticals Files for Chapter 11 Bankruptcy Protection, Expects Nasdaq Delisting
DMK Pharmaceuticals has filed for Chapter 11 bankruptcy and anticipates its stock will be delisted from the Nasdaq.
Worse than expected
DMKPQ
Dmk Pharmaceuticals CORP
8-K: DMK Pharmaceuticals Holds Reconvened Annual Meeting, Elects Directors and Approves Key Proposals
DMK Pharmaceuticals successfully held its reconvened annual meeting, electing five directors, approving amendments to its equity incentive plan, and ratifying its auditor.
Delay expected
DMKPQ
Dmk Pharmaceuticals CORP
8-K: DMK Pharmaceuticals Amends Bylaws, Revising Quorum Requirements for Stockholder Meetings
DMK Pharmaceuticals Corporation has amended its bylaws to change the quorum requirements for stockholder meetings, effective January 22, 2024.